J Korean Diabetes.  2016 Sep;17(3):164-167. 10.4093/jkd.2016.17.3.164.

Glycemic Management of Patients Undergoing Dialysis

• Kim MK

• KMID: 2354280
• DOI: http://doi.org/10.4093/jkd.2016.17.3.164

Abstract

Diabetes mellitus is the leading cause of end-stage renal disease in Korea. The management of glycemic control in patients undergoing dialysis is challenging due to the complexity of the treatment and the lack of convincing data supporting the benefits of tight glycemic control. When kidney function decreased, glucose homeostasis changed. Increased insulin resistance due to uremia and decreased insulin secretion resulted in hyperglycemia, and decreased counter-regulatory hormone and renal gluconeogenesis led to hypoglycemia. Moreover, glycosylated hemoglobin is affected by various factors in patients undergoing dialysis, so it is difficult to monitor for glycemic control. Decreased kidney function changes the pharmacokinetics of drugs. Some oral hypoglycemic agents are used for patients undergoing dialysis, but the main treatment for glycemic control is insulin. Considering these factors, the management of glycemic control for patients undergoing dialysis is delicate and should be individualized based on the patient's risk profile.

Keyword

Dialysis; Glucose

MeSH Terms

Diabetes Mellitus
Dialysis*
Gluconeogenesis
Glucose
Hemoglobin A, Glycosylated
Homeostasis
Humans
Hyperglycemia
Hypoglycemia
Hypoglycemic Agents
Insulin
Insulin Resistance
Kidney
Kidney Failure, Chronic
Korea
Pharmacokinetics
Uremia
Glucose
Hypoglycemic Agents
Insulin

Reference

References

1. Park CW. Diabetic kidney disease: from epidemiology to clinical perspectives. Diabetes Metab J. 2014; 38:252–60.

2. Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus from the Korean Diabetes Association. Diabetes fact sheet in Korea 2015. Seoul: Korean Diabetes Association;2015.

3. Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014; 27:135–45.

4. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012; 60:850–86.

5. Williams ME, Garg R. Glycemic management in ESRD and earlier stages of CKD. Am J Kidney Dis. 2014; 63(2 Suppl 2):S22–38.

6. Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dial. 2010; 23:148–56.

7. Morgan L, Marenah CB, Jeffcoate WJ, Morgan AG. Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure. Diabet Med. 1996; 13:514–9.

8. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Longterm glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2002; 39:297–307.

9. Riveline JP, Teynie J, Belmouaz S, Franc S, Dardari D, Bauwens M, Caudwell V, Ragot S, Bridoux F, Charpentier G, Marechaud R, Hadjadj S. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant. 2009; 24:2866–71.

10. Sobngwi E, Enoru S, Ashuntantang G, Azabji-Kenfack M, Dehayem M, Onana A, Biwole D, Kaze F, Gautier JF, Mbanya JC. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care. 2010; 33:1409–12.

11. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007; 49(2 Suppl 2):S12–154.

12. Abe M, Okada K. DPP-4 Inhibitors in diabetic patients with chronic kidney disease and end-stage kidney disease on dialysis in clinical practice. Contrib Nephrol. 2015; 185:98–115.